Ascidian Therapeutics, a company using technology developed by Jean Bennett, MD, PhD, the F.M. Kirby Professor of Ophthalmology at Penn Medicine, has partnered with Swiss multinational healthcare company Roche to develop RNA therapeutics for neurological diseases. The collaboration combines Ascidian’s RNA exon editing technology with Roche’s expertise in CNS delivery to create novel treatments for hard-to-treat neurological conditions. As part of the agreement Ascidian will receive $42 million upfront and up to $1.8 billion in milestone payments, plus royalties. Read more here.